Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Other Operating Expenses: 2021-2024

Historic Other Operating Expenses for Relay Therapeutics (RLAY) over the last 3 years, with Jun 2024 value amounting to -$11.4 million.

  • Relay Therapeutics' Other Operating Expenses fell 428.53% to -$11.4 million in Q2 2024 from the same period last year, while for Jun 2024 it was -$16.5 million, marking a year-over-year decrease of 57.83%. This contributed to the annual value of -$13.2 million for FY2024, which is 105.64% down from last year.
  • As of Q2 2024, Relay Therapeutics' Other Operating Expenses stood at -$11.4 million, which was down 520.85% from -$1.8 million recorded in Q1 2024.
  • In the past 5 years, Relay Therapeutics' Other Operating Expenses ranged from a high of $134.9 million in Q2 2021 and a low of -$11.4 million during Q2 2024.
  • In the last 3 years, Relay Therapeutics' Other Operating Expenses had a median value of -$1.9 million in 2023 and averaged -$3.1 million.
  • As far as peak fluctuations go, Relay Therapeutics' Other Operating Expenses crashed by 1,361.24% in 2022, and later spiked by 80.40% in 2023.
  • Relay Therapeutics' Other Operating Expenses (Quarterly) stood at $836,000 in 2021, then plummeted by 1,361.24% to -$10.5 million in 2022, then surged by 80.40% to -$2.1 million in 2023, then slumped by 428.53% to -$11.4 million in 2024.
  • Its Other Operating Expenses stands at -$11.4 million for Q2 2024, versus -$1.8 million for Q1 2024 and -$2.1 million for Q4 2023.